215 related articles for article (PubMed ID: 19083133)
1. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Tsavaris N; Lazaris A; Kosmas C; Gouveris P; Kavantzas N; Kopterides P; Papathomas T; Agrogiannis G; Zorzos H; Kyriakou V; Patsouris E
Cancer Chemother Pharmacol; 2009 Jul; 64(2):391-8. PubMed ID: 19083133
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Gouveris P; Lazaris AC; Papathomas TG; Nonni A; Kyriakou V; Delladetsima J; Patsouris ES; Tsavaris N
J Cancer Res Clin Oncol; 2007 Dec; 133(12):1011-5. PubMed ID: 17605046
[TBL] [Abstract][Full Text] [Related]
3. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.
Gao XH; Yu ZQ; Zhang C; Bai CG; Zheng JM; Fu CG
Int J Colorectal Dis; 2012 Apr; 27(4):429-35. PubMed ID: 22076611
[TBL] [Abstract][Full Text] [Related]
7. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
[TBL] [Abstract][Full Text] [Related]
10. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
11. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Hanagiri T; Ono K; Kuwata T; Takenaka M; Oka S; Chikaishi Y; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
J UOEH; 2011 Sep; 33(3):205-16. PubMed ID: 21913377
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
14. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
15. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Shaojun C; Li H; Haixin H; Guisheng L
Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
[TBL] [Abstract][Full Text] [Related]
16. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
Huang Y; Yu H; Lei H; Xie C; Zhong Y
Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]